<DOC>
	<DOCNO>NCT01982201</DOCNO>
	<brief_summary>This study assess potential effect calcium carbonate aluminum/magnesium hydroxide-containing antacid pharmacokinetics ( PK ) pharmacodynamics ( PD ) lesinurad healthy , adult male subject .</brief_summary>
	<brief_title>Antacid Interaction Study</brief_title>
	<detailed_description>In study , lesinurad antacid administer fed state , antacid dos attenuate reflect commonly use dos , baseline PD assessment perform presence absence antacid treatment , sequence treatment ( lesinurad +/- antacid ) randomize .</detailed_description>
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , drug combination</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject body weight ≥ 50 kg ( 110 lb ) body mass index ≥ 18 ≤ 30 kg/m2 . Subject free clinically significant disease medical condition , per Investigator 's judgment Subject history suspicion kidney stone . Subject undergone major surgery within 3 month prior Screening . Subject donate blood experienced significant blood loss ( &gt; 450 mL ) within 12 week prior Screening give plasma donation within 4 week prior Screening . Subject inadequate venous access unsuitable vein repeat venipuncture .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>